DRP1 activity is tumor-promoting in pancreatic and other RAS-driven cancers, but its role in therapeutic resistance is unknown.<h4>Methods</h4>We developed a panel of patient-derived pancreatic cancer cell lines resistant to the MEK inhibitor trametinib. This evidence concerns the gene MAP2K7 and familial pancreatic carcinoma.